Acquisitions, Clinical Trial Results and Stock Price Movements - Research Report on ViroPharma, Pfizer, Alkermes, Tenet, and ResMed PR Newswire NEW YORK, November 14, 2013 NEW YORK, November 14, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting ViroPharma Inc. (NASDAQ: VPHM), Pfizer Inc. (NYSE: PFE), Alkermes plc (NASDAQ: ALKS), Tenet Healthcare Corp. (NYSE: THC), and ResMed Inc. (NYSE: RMD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. ViroPharma Inc. Research Report On November 11, 2013, ViroPharma Inc. (ViroPharma) and Shire plc (Shire) announced that the Board of Directors of both Companies have unanimously approved a merger agreement under which Shire will acquire all outstanding shares of ViroPharma for $50 per share in cash, for a total consideration of approximately $4.2 billion. According to ViroPharma, the $50 per share price in the transaction represents a 64% premium to ViroPharma's unaffected share price of $30.47 on September 12, 2013. Vincent J. Milano, ViroPharma CEO, said, "By joining with Shire, ViroPharma will become part of a larger, more diverse biopharmaceutical company and will benefit from Shire's innovation, scale and global reach. We will have access to resources to expand product distribution, giving us a platform to provide our crucial therapies, such as CINRYZE, to more patients than ever before." Shire CEO, Flemming Ornskov MD commented, "The acquisition of ViroPharma will immediately benefit Shire and is entirely consistent with our clear strategic objective of strengthening our rare disease portfolio." ViroPharma informed that closing of the transaction is subject to customary conditions, including the tender of a majority of the outstanding ViroPharma shares and the receipt of regulatory clearances. The Companies stated that pending anti-trust authority clearances, it expect the transaction to close in Q4 2013, Q1 2014, or as soon as possible thereafter. The Full Research Report on ViroPharma Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/c730_VPHM] Pfizer Inc. Research Report On November 8, 2013, Pfizer Inc. (Pfizer) announced top-line results from a Phase 3B/4 study of RAPAMUNE (sirolimus) evaluating kidney transplant patients who transitioned from tacrolimus-based therapy (TAC) to RAPAMUNE 3 to 5 months after transplant. According to Pfizer, the primary endpoint of the study was not achieved as there was not a statistically significant difference in renal function improvement between patients who continued receiving TAC and those who switched to RAPAMUNE. Pfizer added that for patients who were switched to RAPAMUNE, 33.7% of patients achieved the primary endpoint of a ≥ 5 ml/min/1.73m2 renal function improvement based on glomerular filtration rate (GFR) from randomization to 24 months post-transplantation, and 42.3% of patients continuing to take TAC achieved the primary endpoint (p=0.239). The Company informed that RAPAMUNE is indicated for the prevention of organ transplant rejection in kidney transplant patients aged 13 years and older in the US. Pfizer further stated that the study was an open-label, randomized, comparative, multi-center, multi-national study conducted in Europe, Latin America, North America, and the Pacific Region. Pfizer also informed that there were 256 subjects in the study randomized at 3 to 5 months after transplant, with two subjects not receiving any medication. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/d702_PFE] Alkermes plc Research Report On November 11, 2013, Alkermes plc's stock rose 1.77%, ending the day at $36.76. Over the previous three trading sessions, shares of Alkermes gained 4.58%, compared to the Nasdaq Composite which declined 0.31% and the Dow Jones Industrial Average which gained 0.23% during the same period. The Full Research Report on Alkermes plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e2f3_ALKS] Tenet Healthcare Corp. Research Report On November 11, 2013, Tenet Healthcare Corp.'s stock (Tenet) declined 0.52%, ending the day at $42.11. Over the previous three trading sessions, shares of Tenet declined 3.79% compared to the S&P 500 which gained 0.08% and the Dow Jones Industrial Average which gained 0.23% during the same period. The Full Research Report on Tenet Healthcare Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/1d25_THC] ResMed Inc. Research Report On November 11, 2013, ResMed Inc.'s stock (ResMed) gained 0.26%, ending the day at $50.74. Over the previous three trading sessions, shares of ResMed gained 1.72% compared to the S&P 500 which gained 0.08% and the Dow Jones Industrial Average which gained 0.23% during the same period. The Full Research Report on ResMed Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/bd44_RMD] EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://www.analystscorner.com/ SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Acquisitions, Clinical Trial Results and Stock Price Movements - Research Report on ViroPharma, Pfizer, Alkermes, Tenet, and
Press spacebar to pause and continue. Press esc to stop.